Shares of Cortexyme (NASDAQ: CRTX) , a clinical-stage biotechnology company, are collapsing in response to a clinical trial failure. Investors upset with the results had hammered the stock 74.9% lower as of 12:14 p.m. EDT on Wednesday.
Cortexyme's former lead candidate, atuzaginstat, is an experimental inhibitor of an enzyme secreted by Porphyromonas gingivalis . This microbe is found in the mouths of people with severe gum disease, and it's also been associated with Alzheimer's dementia.
Image source: Getty Images.
For further details see:
Here's Why Cortexyme Is Imploding on Wednesday